Ketogenic dietary interventions in autosomal dominant polycystic kidney disease-a retrospective case series study: first insights into feasibility, safety and effects.
autosomal dominant polycystic kidney disease
caloric restriction
intermittent fasting
ketogenic diet
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
16
04
2021
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Our laboratory published the first evidence that nutritional ketosis, induced by a ketogenic diet (KD) or time-restricted diet (TRD), ameliorates disease progression in polycystic kidney disease (PKD) animal models. We reasoned that, due to their frequent use for numerous health benefits, some autosomal dominant PKD (ADPKD) patients may already have had experience with ketogenic dietary interventions (KDIs). This retrospective case series study is designed to collect the first real-life observations of ADPKD patients about safety, feasibility and possible benefits of KDIs in ADPKD as part of a translational project pipeline. Patients with ADPKD who had already used KDIs were recruited to retrospectively collect observational and medical data about beneficial or adverse effects and the feasibility and safety of KDIs in questionnaire-based interviews. A total of 131 ADPKD patients took part in this study. About 74 executed a KD and 52 a TRD for 6 months on average. A total of 86% of participants reported that KDIs had improved their overall health, 67% described improvements in ADPKD-associated health issues, 90% observed significant weight loss, 64% of participants with hypertension reported improvements in blood pressure, 66% noticed adverse effects that are frequently observed with KDIs, 22 participants reported safety concerns like hyperlipidemia, 45 participants reported slight improvements in estimated glomerular filtration rate and 92% experienced KDIs as feasible while 53% reported breaks during their diet. Our preliminary data indicate that KDIs may be safe, feasible and potentially beneficial for ADPKD patients, highlighting that prospective clinical trials are warranted to confirm these results in a controlled setting and elucidate the impact of KDIs specifically on kidney function and cyst progression.
Sections du résumé
Background
UNASSIGNED
Our laboratory published the first evidence that nutritional ketosis, induced by a ketogenic diet (KD) or time-restricted diet (TRD), ameliorates disease progression in polycystic kidney disease (PKD) animal models. We reasoned that, due to their frequent use for numerous health benefits, some autosomal dominant PKD (ADPKD) patients may already have had experience with ketogenic dietary interventions (KDIs). This retrospective case series study is designed to collect the first real-life observations of ADPKD patients about safety, feasibility and possible benefits of KDIs in ADPKD as part of a translational project pipeline.
Methods
UNASSIGNED
Patients with ADPKD who had already used KDIs were recruited to retrospectively collect observational and medical data about beneficial or adverse effects and the feasibility and safety of KDIs in questionnaire-based interviews.
Results
UNASSIGNED
A total of 131 ADPKD patients took part in this study. About 74 executed a KD and 52 a TRD for 6 months on average. A total of 86% of participants reported that KDIs had improved their overall health, 67% described improvements in ADPKD-associated health issues, 90% observed significant weight loss, 64% of participants with hypertension reported improvements in blood pressure, 66% noticed adverse effects that are frequently observed with KDIs, 22 participants reported safety concerns like hyperlipidemia, 45 participants reported slight improvements in estimated glomerular filtration rate and 92% experienced KDIs as feasible while 53% reported breaks during their diet.
Conclusions
UNASSIGNED
Our preliminary data indicate that KDIs may be safe, feasible and potentially beneficial for ADPKD patients, highlighting that prospective clinical trials are warranted to confirm these results in a controlled setting and elucidate the impact of KDIs specifically on kidney function and cyst progression.
Identifiants
pubmed: 35664270
doi: 10.1093/ckj/sfab162
pii: sfab162
pmc: PMC9155228
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1079-1092Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK124895
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of ERA.
Références
JAMA. 2003 Aug 20;290(7):912-20
pubmed: 12928468
J Am Soc Nephrol. 2016 Jul;27(7):1958-69
pubmed: 26534924
Epilepsia. 2004 Sep;45(9):1116-23
pubmed: 15329077
Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1765-1776
pubmed: 30049849
Nat Med. 2013 Apr;19(4):488-93
pubmed: 23524344
Nat Rev Nephrol. 2012 Feb 21;8(5):293-300
pubmed: 22349487
Am J Physiol Renal Physiol. 2016 Apr 15;310(8):F726-F731
pubmed: 26764208
Front Nutr. 2020 Mar 13;7:20
pubmed: 32232045
Clin Kidney J. 2018 Dec;11(Suppl 1):i27-i38
pubmed: 30581563
Lipids. 2008 Jan;43(1):65-77
pubmed: 18046594
Eur J Clin Nutr. 2013 Aug;67(8):789-96
pubmed: 23801097
Br J Nutr. 2016 Aug;116(4):632-8
pubmed: 27346534
J Am Soc Nephrol. 2018 Feb;29(2):571-578
pubmed: 29118087
Nutrients. 2020 Jan 27;12(2):
pubmed: 32012661
Dev Med Child Neurol. 2006 Dec;48(12):978-81
pubmed: 17109786
Kidney Int. 2019 Aug;96(2):429-435
pubmed: 31084924
Science. 2018 Nov 16;362(6416):764-770
pubmed: 30442800
Diabetes Care. 2013 Aug;36(8):2225-32
pubmed: 23690533
Am J Nephrol. 2012;36(4):362-70
pubmed: 23038404
N Engl J Med. 2008 Jul 17;359(3):229-41
pubmed: 18635428
Nutr Metab (Lond). 2009 Aug 10;6:31
pubmed: 19664276
J Clin Endocrinol Metab. 2004 Jun;89(6):2717-23
pubmed: 15181047
Diabetes Metab Res Rev. 1999 Nov-Dec;15(6):412-26
pubmed: 10634967
Kidney Int. 2019 May;95(5):1253-1261
pubmed: 30922668
Clin J Am Soc Nephrol. 2021 Jun;16(6):908-915
pubmed: 34117082
Lancet. 2019 Mar 2;393(10174):919-935
pubmed: 30819518
Kidney Int Rep. 2019 Jan 14;4(4):606-609
pubmed: 30993236
Nat Med. 2003 Oct;9(10):1323-6
pubmed: 14502283
J Am Soc Nephrol. 2016 May;27(5):1437-47
pubmed: 26538633
PLoS One. 2013 Dec 13;8(12):e81835
pubmed: 24349134
Prostaglandins Leukot Essent Fatty Acids. 2004 Mar;70(3):309-19
pubmed: 14769489
High Blood Press Cardiovasc Prev. 2015 Dec;22(4):389-94
pubmed: 25986079
J Am Coll Cardiol. 2008 Jan 1;51(1):59-67
pubmed: 18174038
Clin Nephrol. 2020 Jun;93(6):307-309
pubmed: 32000887
PLoS One. 2014 May 22;9(5):e97656
pubmed: 24852037
N Engl J Med. 2017 Nov 16;377(20):1930-1942
pubmed: 29105594
J Child Neurol. 2007 Apr;22(4):375-8
pubmed: 17621514
Circulation. 2017 Jul 18;136(3):e1-e23
pubmed: 28620111
J Am Soc Nephrol. 2015 Jan;26(1):160-72
pubmed: 24904092
Br J Nutr. 2016 Feb 14;115(3):466-79
pubmed: 26768850
J Am Soc Nephrol. 1993 Nov;4(5):1159-71
pubmed: 8305642
J Clin Invest. 2019 Jul 30;129(10):4506-4522
pubmed: 31361604
Br J Nutr. 2016 Mar 28;115(6):1126-8
pubmed: 26858234
Lipids. 2009 Apr;44(4):297-309
pubmed: 19082851
Lancet Neurol. 2008 Jun;7(6):500-6
pubmed: 18456557
Nutrients. 2018 Jun 16;10(6):
pubmed: 29914176
Kidney Int. 2009 Jan;75(2):235-41
pubmed: 18971924
Curr Neurol Neurosci Rep. 2006 Jul;6(4):332-40
pubmed: 16822355
EBioMedicine. 2016 Jan 26;5:183-92
pubmed: 27077126
Ann Intern Med. 2013 Sep 17;159(6):382-9
pubmed: 24042366
Cell Metab. 2019 Dec 3;30(6):1007-1023.e5
pubmed: 31631001